Clinical Trial Update: Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating recombinant human antithrombin (ATryn) for disseminated intravascular coagulation in patients with severe sepsis. The study was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Disseminated Intravascular Coagulation

Drugs mentioned

• ATryn (recombinant human antithrombin)

Snippet

Sponsor: LEO Pharma | Conditions: Disseminated Intravascular Coagulation | Phase 2 | Status: TERMINATED | Results posted: 2021-08-31